Fig. 1

Suggested approach to treatment after anti-angiogenesis therapy. Suggested algorithm for treatment options for mRCC. Sunitnib and pazopanib are recommended in the first-line setting, with the exception of selected patients who may benefit from temsirolimus or IL-2. Upon disease progression, second-line agents can be chosen at the discretion of the clinician. The algorithm provided is based on current clinical data and practice guidelines